New hope for tough cancers: CBX-12 drug trial begins
NCT ID NCT04902872
First seen May 15, 2026 · Last updated May 15, 2026
Summary
This study tested a new drug called CBX-12 in 69 adults with advanced solid tumors (like ovarian, lung, or breast cancer) that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was completed, but results are not yet reported.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
NEXT Oncology
Austin, Texas, 78758, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
Yale Cancer Center
New Haven, Connecticut, 06511, United States
Conditions
Explore the condition pages connected to this study.